Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD
Hannes Hagström, Patrik Nasr, Mattias Ekstedt et al. · Journal of Hepatology · 2017
Cited by 1,063 works. doi:10.1016/j.jhep.2017.07.027
Authors
References
- Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
- Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes
- External review and validation of the Swedish national inpatient register
- Long‐term follow‐up of patients with NAFLD and elevated liver enzymes†‡
- The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association
- Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease
- The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research
- Nonalcoholic Fatty Liver Disease: From Steatosis to Cirrhosis
- Prevalence of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among a Largely Middle-Aged Population Utilizing Ultrasound and Liver Biopsy: A Prospective Study
- Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up